Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine Treatment on Cognition in Alzheimer's Disease
NCT04570085Phase 3Recruiting
- Sponsor
- CHU de Lille
- Start
- Mar 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of caffeine in Alzheimer's disease (AD), sponsored by CHU de Lille. Started Mar 2021; status: recruiting.
02
Drugs
caffeine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04570085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04570085.